Phase 3 N=421 Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)
Asthma
Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 — 9.53; 9.15 Percent Change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=46 Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
Asthma
Primary: Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge — 0.822; 6.468 Percent — p=0.0208
Phase 2 N=27 Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
Asthma
Primary: Maximum Percent Drop From Pre-allergen Baseline in Forced Expiratory Volume in 1 Second (FEV1) for Late-Phase Asthma Response (LAR) at Screening — 27.19; 20.47 percent…
Phase 4 N=191 Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)
Asthma · Allergic Rhinitis
Primary: Change From Baseline for Daytime Asthma Symptom Score — 0.32; 0.16; 0.29; 0.13 Units on scale — p=0.015
Phase 2 N=24 A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics
Asthma
Primary: Late Asthmatic Response (LAR): Minimum FEV1 Between 4-10 Hours After Allergen Challenge on Day 13 of Each Treatment Period — -0.903; -0.663; -0.638; -0.446 Liters
Phase 1 N=16 Early Airway Response to Allergen in Asthmatics (MK-0000-176)
Asthma
Primary: Change in Forced Expiratory Volume in 1 Second (FEV1) — -24.66; -8.44; -9.15; -16.17 Percentage drop in FEV1 — p=<0.0001
Phase 2 N=20 The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen
Asthma
Primary: Late Allergic Response (LAR) by Assessment of Minimum Percentage of FEV1 3-7 Hours Post Allergen Challenge Compared to Pre Allergen Challenge FEV1 — 90.97; 91.32; 87.28…
Phase 2 N=28 Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics
Asthma
Primary: Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With…
Phase 2 N=8 A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
Atopic Asthma
Primary: Number of Subjects With Serious Adverse Events — 0; 0 participants
Phase 4 N=313 Singulair(R) In Asthma And Allergic Rhinitis (0476-383)
Asthma
Primary: Asthma Control — 312; 72; 0; 229 Participants
Phase 2 N=58 Allergy Immunotherapy for the Reduction of Asthma
Wheezing · Asthma · Allergy
Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38
Phase 2 N=19 Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)
Asthma
Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 3 to 7 Hours (AUC3-7hr) After Allergen Challenge Following 9 Days…
Phase 3 N=211 Characterization of the Role of Histamine in Children With Asthma
Asthma · Allergic Asthma · Non-allergic Asthma
Primary: Characterize Contribution of Histamine in Children With Asthma — 11253.24; 6464.20; 3539.67 flux units on a continuous scale
Phase 2 N=24 The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics
Atopic Asthma
Primary: Baseline Percentage of Eosinophils Recovered in the BAL Prior to Segmental Allergen Challenge — 42; 19 percentage of cells
Phase 1 N=31 Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma
Asthma
Primary: Maximum Percentage Decrease in Forced Expiratory Volume in 1 Second (FEV1) at 3 to 7 Hours Post Allergen Challenge — -20.645; -16.949; -19.366; -12.064 percent change…
Phase 2 N=61 A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
Allergic Asthma
Primary: Change in Logarithmically Transformed (log2) Allergen PC15 Concentration (Allergen Concentration Required to Evoke a 15% Decrease in FEV1) — 1.15; 1.85; 0.36…
Phase 4 N=32 Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
Asthma
Primary: Short-term Lower Leg Growth During Treatment With Flovent Diskus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID. — 0.37; 0.21 mm/wk
Phase 2 N=93 Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)
Asthma · Airway Inflammation
Primary: Mean Percent Change From Baseline to Day 14 in Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb) — -35.3; -45.4; -61.4; -51.3 percentage of eNO — p=<0.001
Phase 3 N=51 An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma
Allergic Rhinitis · Asthma
Primary: The Change of the Rhinasthma Global Summary Score From Baseline to Endpoint After 28 Days of Treatment. — 25.3; 26.7; -10.3; 0.4 units on a scale — p=0.001
Phase 2 N=36 Effect of the GSK2245035 on the Allergen-induced Asthmatic Response
Asthma
Primary: Late Asthmatic Response (LAR): Absolute Change From Saline in Minimum Forced Expiratory Volume in 1 Second (FEV1) Between 4-10 Hours Following Allergen Challenge One…
Phase 4 N=13 A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
ALLERGIC ASTHMA
Primary: Number of Participants With Change in Sputum Markers by End of Study — 0; 0 Participants
Phase 3 N=295 Steroids In Eosinophil Negative Asthma
Asthma
Primary: Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1. — 74; 35; 56; 12 Participants…
Phase 3 N=300 Individualized Therapy For Asthma in Toddlers
Asthma · Wheezing
Primary: Differential Response to the Three Therapies Based on Fixed Threshold Criteria for the Following Asthma Control Measures: Use of Oral Prednisone for Acute Asthma…
N/A N=18 Immune Dysfunction in Allergic Asthma
Asthma
Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…
Phase 3 N=1,771 Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)
Asthma
Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510
Phase 2 N=301 A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
Asthma
Primary: Change in FEV1 — -0.40; 0.69; -0.59 percentage of change
Phase 3 N=20 Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
Allergic Asthma
Primary: Change in Exhaled Nitric Oxide From Baseline to Week 12 — -11.0 parts per billion (ppb) — p=0.005
Phase 1 N=27 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
Asthma
Primary: Number of Participants Who Experienced One or More Adverse Events — 9; 3 Participants
N/A N=7 Imaging Study of the Lungs During an Allergic Asthma Attack
Asthma · Atopy
Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage
N/A N=38 Eosinophilic Airway Inflammation and Mepolizumab
Asthma
Primary: The Primary Endpoint of the Study is the Percent of Eosinophils in the Bronchoalveolar Lavage Fluid After Segmental Allergen Challenge, Before and After Mepolizumab…